AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02799628 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: intervention
Description: intervention with recommendation and therapist introduction
Study NCT02799628 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: low back pain education, and physical therapy 3 times per week
Study NCT02799628 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: low back pain education, and physical therapy 3 times per week
Study NCT01689324 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: (ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis
Description: 0.5 mL, Intramuscular
Study NCT00112684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00112684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00112684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02256189 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo one tablet daily
Study NCT04329533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calm is a mindfulness meditation mobile app
Description: Mindfulness meditation is a self-management strategy that can be utilized to assist with the management of stress. Mindfulness meditation mobile applications, such as the Calm app, can be used to help manage stress, especially during this uncertain time.
Study NCT02172846 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton beam radiation therapy (PBT)
Study NCT02172846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02172846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT01473524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets were administered orally once daily.
Study NCT02389530 — intervention group
Intervention type: DRUG
Intervention: Fluorescein
Description: Fluorescein will be administered intravenously at a dose between 250 mg and 400 mg in the experimental arm.
Study NCT01116310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L)
Description: Bottles containing 60 capsules, 53.5 mg/capsule of isoflavones
Study NCT01116310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Bottles containing 60 capsules.
Study NCT01116310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bottles containing 60 capsules.
Study NCT03437629 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Temporary cement based on Calcium Hydroxide
Description: Confection of a temporary crown with acrylic resin; Finishing and polishing; relative isolation with cotton and gauze; Manipulation of the temporary cement based on Calcium Hydroxide; Cement insertion on the internal surface of the temporary crown; Excess cement removal; Occlusal Adjustment.
Study NCT03437629 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MTA temporary cement
Description: Confection of a temporary crown with acrylic resin; Finishing and polishing; relative isolation with cotton and gauze; Manipulation of the temporary cement based on Mineral trioxide aggregate; Cement insertion on the internal surface of the temporary crown; Excess cement removal; Occlusal Adjustment.
Study NCT00668772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium/Salmeterol
Description: Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
Study NCT00668772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium/Salmeterol QD + Salmeterol
Description: Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
Study NCT00668772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
Study NCT00668772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Salmeterol Inhalation Powder, hard PE capsule
Study NCT00668772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
Study NCT00263601 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovit 6-grasses
Description: Subcutaneous injections
Study NCT00263601 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injections
Study NCT00661167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: ABI-007 260 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
Study NCT02512276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telepharmacist intervention
Description: The intervention consists of a brief telephonic consultation with a clinical pharmacist using behavioral interviewing techniques tailored to patient's level of health activation and progress reports of medication-taking and disease control. Based on the barriers identified during the initial telephone consultation, patients will be offered more intensive support including reminder and motivational text-messages, video visits and pillboxes.
Study NCT03565991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: IV treatment
Study NCT03565991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Oral treatment
Study NCT04067011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500Mg Tablet
Description: Ciprofloxacin 500mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 4-9, 22-24 and 31-37.
Study NCT04067011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 100Mg Tablet
Description: Doxycycline 100mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 2-9, 22-24 and 32-38.
Study NCT04067011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909
Description: 0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose.The vaccine will be administered intramuscularly on Study Days 8 and 23.
Study NCT01461798 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: assessment of efficacy of Benecol yogurt
Description: Benecol Yogurt and Yogurt placebo for 4 weeks each, at a dose of 100 ml (200 ml in total) of yogurt twice a day with main meals
Study NCT01461798 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Yogurt
Description: Yogurt without the active principle
Study NCT01461798 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: yogurt
Description: yogurt without plant stanols
Study NCT00647907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Oral or intravenous voriconazole. Oral tablets 400 mg twice daily loading dose on first day, followed by 200 mg twice daily taken at least 1 hour before or after a meal. Oral doses could be increased to a maximum of 300 mg twice daily if there was no clinical improvement after at least 3 days of treatment, no serious adverse events were reported, and clinical chemistry parameters were within the acceptable range for study entry. Intravenous treatment was initiated with a loading dose of 6 mg/kg twice daily for the first day followed by 4 mg/kg twice daily for at least 3 days (maximum infusion rate of 3 mg/kg/hr if administered by peripheral intravenous line). An intravenous loading dose was not required in patients who were restarted after oral treatment. Total duration of therapy (intravenous and oral) was 12 weeks.
Study NCT04429438 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2
Description: Patients who have relapsed and refractory B cell lymphoma (BCL) after conventional chemotherapy will be treated with multiple 4SCAR gene-engineered T cells
Study NCT02437240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilates-based CPT
Description: To emphasize the self-perception of breathing and body core control during in-patient cardiopulmonary physical therapy following cardiac surgery
Study NCT02437240 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional CPT
Description: A traditional in-patient cardiopulmonary physical therapy following cardiac surgery including airway clearance, breathing exercises, chest mobility and reconditioning exercises and so on
Study NCT01840865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: brain stimulation
Description: oscillating direct current brain stimulation
Study NCT01840865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: no stimulation
Description: sham Stimulation
Study NCT03665441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eryaspase
Description: L-asparaginase encapsulated in erythrocytes (red blood cells)
Study NCT03665441 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine plus Abraxane
Description: gemcitabine, Abraxane
Study NCT03665441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Abraxane
Description: gemcitabine, Abraxane
Study NCT03665441 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan plus 5-FU plus leucovorin
Description: irinotecan, 5-FU, leucovorin
Study NCT03665441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan plus 5-FU plus leucovorin
Description: irinotecan, 5-FU, leucovorin
Study NCT02728843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: 600 mg tablets
Study NCT02728843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets that match the deferiprone tablets in appearance
Study NCT04152018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06940434
Description: PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated
Study NCT00879957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin
Description: Heparin will be added to PICC infusions at a dose of 0.5 units heparin per milliliter of intravenous fluid/parenteral nutrition.
Study NCT00879957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No heparin
Description: In the no heparin group, the subjects will not receive heparin as an additive to their PICC infusions.
Study NCT03670290 — intervention group
Intervention type: PROCEDURE
Intervention: Fascia iliaca compartment catheter
Description: Patient will evaluate and if VAS score >3, catheter will be inserted and 30 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS>3 or patient enounce pain.
Study NCT01013376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC-1101
Description: MC-1101 1.0%
Study NCT01013376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle
Study NCT04073654 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of dental implants (surgical procedure)
Description: The two study implants have to be placed in the same surgical session according to similar procedures. Implants will be placed in the planned anatomic sites by using a flapless or a miniflap approach. Implants sites will be prepared based on the bone density, and according to the manufacturers's instruction by using the 122 Taper kit (Osstem Implant).
Study NCT04073654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of dental implants (surgical procedure)
Description: The two study implants have to be placed in the same surgical session according to similar procedures. Implants will be placed in the planned anatomic sites by using a flapless or a miniflap approach. Implants sites will be prepared based on the bone density, and according to the manufacturers's instruction by using the 122 Taper kit (Osstem Implant).
Study NCT02332798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm
Study NCT02332798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study NCT02535117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Surgery(LS)
Description: For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
Study NCT02535117 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
Study NCT01195558 — intervention group
Intervention type: OTHER
Intervention: Data collection on blindness and sleep problems
Description: Data related to degree of vision impairment and sleep problems is collected through a phone or web survey
Study NCT01980394 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Esophageal Stump Washout
Description: a washout of the closed esophageal stump with Ringer-solution (10 times 30ml) is performed by means of a transorally inserted 24F-Foley catheter. The first, fifth and tenth portion of the lavage fluid are collected and sent to cytological examination
Study NCT04478539 — intervention group
Intervention type: DEVICE
Intervention: Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter
Description: Admitted patients will receive at least 1 cycle of extracorporeal blood purification using the oXiris® (AN69ST) hemofilter (Baxter, IL, USA). The number of cycles of blood purification is determined based on multiple biochemical, immunological, coagulation parameters, radiological imaging and overall clinical condition.~The patient is connected to the Prismaflex® oXiris® system via a double lumen catheter placed in the femoral vein or vena subclavia.~Flow rates will be maintained as follow; effluent dose 35 mL/Kg/h, dialysate 14 - 16 mL/Kg/h, blood 150 mL/min, replacement 16 -18 mL/Kg/h; patient fluid removal is tailored to the individual's volume status, ≈ 100 - 250 mL/h.~The oXiris® extracorporeal and organ support modality will be chosen according to the patient's kidney function; continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF) or slow continuous ultrafiltration (SCUF).
Study NCT04152018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: PF-06801591 will be administered subcutaneously on Day 1 of each 28 day cycle or Day 1 of each 21 day cycle.
Study NCT01393691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT with parent involved play
Description: This is a CBT adaptation designed for preschool children, which includes multiple standard cognitive-behavioral techniques, namely psycho-education, problem solving via play, gradual exposure and reinforcement management.
Study NCT01393691 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Triadic expressive play therapy
Description: Based on expressive play therapy guidelines, children and their parents will express themes concerning bedtime routines and fears via play.
Study NCT02611219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Health Module-Baseline Adolescent-Self Report (13-18 years)
Description: * 38 question questionnaire~* Answers range from 1=all of the time to 5=none of the time
Study NCT02611219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Health Module-Follow Up Adolescent-Self Report (13-18 years)
Description: * 38 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time
Study NCT02611219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Health Module-Baseline Parent Report-Adolescent (13-18 years)
Description: * 38 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time
Study NCT02611219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Health Module-Follow Up Parent Report-Adolescent (13-18 years)
Description: * 38 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time
Study NCT02611219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Health Module-Baseline Parent Report-School Age (5-12 years)
Description: * 34 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time
Study NCT02611219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Health Module-Follow Up Parent Report-School Age (5-12 years)
Description: * 34 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time
Study NCT02611219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Demographic Data Form
Description: -16 questions about demographics such as household income, race, and gender
Study NCT02260856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tantalum Beads & Injector
Description: To measure growth at physis, four tantalum beads will be implanted per physis at baseline and take radiostereometric analysis measurements at all follow up timepoints. Tantalum beads have been used to make detailed three dimensional radiographic measurements in orthopedic and other specialties
Study NCT03670290 — intervention group
Intervention type: PROCEDURE
Intervention: epidural catheter
Description: Patient will evaluate and if VAS score >3, catheter will be inserted and 10 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS>3 or patient enounce pain.
Study NCT03670290 — intervention group
Intervention type: PROCEDURE
Intervention: patient controlled analgesia
Description: Patient will evaluate and if VAS score >3, patient controlled analgesia pump will be set 1mg morphine/15 min lockout.
Study NCT02611219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCT Daily Activity Log
Description: * Uses Fitbit Flex~* Log that lists time in 15 minute increments and allows for checking when out of bed and describing the activity that occurred while out of bed
Study NCT03002571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-124 Lotion
Description: IDP-124 Lotion, twice-daily application
Study NCT03002571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-124 Vehicle Lotion
Description: IDP-124 Vehicle Lotion, twice-daily application
Study NCT00566566 — intervention group
Intervention type: OTHER
Intervention: sample without DNA
Description: family history, anthropometric measurements and blood sampling
Study NCT02260856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tantalum Beads & Injector
Description: To measure growth at physis, four tantalum beads will be implanted per physis at baseline and take radiostereometric analysis measurements at all follow up timepoints. Tantalum beads have been used to make detailed three dimensional radiographic measurements in orthopedic and other specialties
Study NCT02260856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Drill Epiphysiodesis
Study NCT00562237 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: S205 placebo
Description: 2 i.m. injections per subject (0.5 mL each)
Study NCT02260856 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Screw Epiphysiodesis
Study NCT02611219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Functional Independence Measure for Children
Description: * 18-item, 7-level ordinal scale instrument that measures a child's consistent performance in essential daily functional skills. Three main domains (selfcare, mobility, and cognition) are assessed by interviewing or by observing a child's performance of a task to criterion standards~* Categorized into 2 main functional streams: Dependent (ie, requires helper: scores 1-5) and Independent (ie, requires no helper: scores 6-7). Scores 1 (total assistance) and 2 (maximal assistance) belongs to the Complete Dependence category. Scores 3 (moderate assistance), 4 (minimal contact assistance), and 5 (supervision or set-up) belongs to the Modified Dependence category. Scores 6 (modified independence) and 7 (complete independence) belongs to the Independent category.
Study NCT02611219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Muscle Testing
Description: -Isometric muscle strength is tested in specific positions, usually with the muscle at an optimal working length. Using a break test, the test giver overpowers the muscle being tested to determine the muscle grade.